Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Philadelphia nonprofit opens 'Cares Center' to assist patients and families battling cancer on February 21, 2019 at 10:38 am
The program named in her honor will “provide tutoring to children with cancer in an effort to help balance treatment and academics.” “This is the start of trying to change the stories I'm hearing [pat... […]
- Scientists uncover how high-fat diet drives colorectal cancer growth on February 21, 2019 at 10:31 am
"While colon cancer is considered 'incurable,' Ting's work opens up an entirely new frontier in the understanding and treatment of the disease," says Evans. […]
- Immunotherapy cancer treatment puts Hellam Twp. teen in remission on February 21, 2019 at 10:03 am
Immunotherapy cancer treatment puts Hellam Twp. teen in remission A Hellam Township teen is in remission after fighting cancer with his own genetically-modified cells. Check out this story on yorkdisp... […]
- Genomics Guide Treatment Escalation, De-Escalation in HR+ Breast Cancer on February 21, 2019 at 9:52 am
A greater understanding of the genomics of patients with hormone receptor (HR)–positive breast cancer is enabling physicians to offer more personalized de-escalated and escalated treatment strategies ... […]
- PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy on February 21, 2019 at 9:09 am
Newswise — In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a bio... […]
- Myovant- "Value Creation" in Cancer Treatment on February 21, 2019 at 8:03 am
In their most recent quarterly update, the company highlighted Relugolix and emphasized that all important timelines remain on track for top-line Phase III data readouts in uterine fibroids from ... […]
- After the Diagnosis: Treatment Options for Kidney Cancer on February 21, 2019 at 6:48 am
Most often, the cancer is found incidentally. A CT, or computed tomography, scan is done, for instance, because a person has abdominal pain or some other (usually unrelated) symptoms. And when ... […]
- Keytruda May Play a Role in Treatment of Patients with Non-Muscle Invasive Bladder Cancer on February 21, 2019 at 6:28 am
After patients with non–muscle invasive bladder cancer fail to respond to treatment with Bacillus Calmette-Guérin (BCG) immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk ... […]
- Alliance for Cancer Gene Therapy honors cancer pioneer Dr. Carl June at April 18 Gala on February 21, 2019 at 6:16 am
Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to funding cancer cell and gene therapy research, is celebrating its 18th anniversary with a very special Awa... […]
via Bing News